Appetite loss during chemotherapy is not simply a failure of willpower. Nausea, early fullness, altered taste, constipation, pain, inflammation and the metabolic changes of cancer can all make eating difficult. A familiar anti-nausea medicine—olanzapine—has now produced a surprisingly large appetite and weight signal in a randomized trial.
Evidence at a glance
- Studied population: 124 adults starting chemotherapy for untreated locally advanced or metastatic gastric, hepatopancreaticobiliary or lung cancer.
- Intervention: oral olanzapine 2.5 mg once daily for 12 weeks versus placebo, alongside nutritional assessment and dietary advice.
- Meaningful benefit: more than 5% weight gain occurred in 60% with olanzapine versus 9% with placebo; appetite improved in 43% versus 13%.
- Negative finding: the trial did not establish improvement in muscle mass, strength, survival or long-term function.
- Boundary: improving appetite is supportive care, not cancer control.
What makes this study important
The double-blind randomized trial enrolled people with a substantial nutrition problem: almost everyone reported anorexia, more than half had already lost over 5% of their prediagnosis weight, and about one-third were underweight. The groups received the same nutrition assessment and dietary guidance, making the added medication the main difference.
At 12 weeks, the separation was unusually large: 60% versus 9% achieved at least 5% weight gain. Appetite improved in 43% versus 13%. Severe chemotherapy toxicity was also less common in the olanzapine group, although that secondary result should not be treated as proof that the drug makes chemotherapy safer in every setting.
In response, ASCO updated its cancer-cachexia guidance to say that low-dose olanzapine may be offered to adults with advanced cancer who have appetite and weight loss. “May be offered” is appropriately different from “should be prescribed to everyone.”
Weight is not the whole outcome
Cancer cachexia involves inflammation and muscle loss, not only inadequate calories. The study did not show how much of the added weight was muscle, fluid or fat, and it did not prove better strength or survival. Appetite treatment should sit beside dietitian support, symptom control, pancreatic enzymes when indicated, and activity or rehabilitation when safe.
Safety deserves an individual review
Olanzapine can cause sleepiness, dizziness, constipation, dry mouth and orthostatic hypotension, which can increase fall risk. It can also raise glucose and lipids. Those issues matter more in someone already weak, dehydrated, diabetic or taking other sedating or blood-pressure-lowering drugs. Although treatment-attributed toxicity was low in this 2.5-mg trial, a prescription still requires medication reconciliation and monitoring.
Questions for your care team
- What is driving my appetite loss—nausea, constipation, pain, obstruction, depression or cachexia?
- Would olanzapine duplicate medicine I already receive for nausea?
- How would we monitor sedation, falls, glucose and constipation?
- Are we tracking strength and function as well as body weight?
Explore the Missing Script evidence library, and follow the podcast, coming soon. The study dose describes research, not personal prescribing. This article is educational and is not a substitute for individualized medical care.
